Active Filter(s):
Details:
The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus with modified glycoprotein platform and cancer vaccines platforms.
Lead Product(s): Modified Oncolytic virus
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 09, 2020